A proposal to buy out Soleno Therapeutics Inc. didn’t wait for European approval of Vykat XR (diazoxide choline) to treat hyperphagia in Prader-Willi syndrome, as Neurocrine Biosciences Inc. is putting on the table $53 per share in cash, which equates to an equity value of $2.9 billion. Read More
After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. However, depending on the drug, where it’s made and whether a manufacturer has reached onshoring and pricing agreements with the Department of Health and Human Services, the actual tariff could be as low as 0%. Read More
Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. Read More
Do state laws requiring drug companies to give steep 340B drug discounts to an unlimited number of contract pharmacies, with no claims data required, interfere with a longstanding contract between the U.S. Congress and biopharma? Or do such laws merely flex states’ authority over pharmacy practices such as delivery? Read More
Swedish startup One-carbon Therapeutics AB is going after solid tumors with an approach that looks similar to synthetic lethals to some people, and to chemotherapy to others. But One-carbon CEO Ana Slipicevic said that TH-9619, the company’s first-in-class inhibitor of the enzyme MTHFD1/2, is neither of those things. Read More
Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024. Read More
New hires and promotions in the biopharma and med-tech industries, including: Akebia, Clarametyx, Coya, Curve, Harmony, Royal, Orionis, Pavmed, Telix. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Adagene, Arch Biopartners, Celldex, Entera, Hoth, Inovio, Stairmed. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Adagene, Alto Neuroscience, Astrazeneca, Beam, Immunovant, Lipocine, Neutrolis, Novo Nordisk, Pangia, Puretech, Seaport, Soligenix, Vascarta. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Adagene, Axsome, Boston Scientific, BSM, Ellipsys, Gilead, Incyte, Lupin, Oncotelics, Phil, Shionogi, Takeda, Tanabe, Techforce, Tenpoint, Valencia, Visufarma. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Cocrystal, Context, Fore, Eli Lilly, Merck, Ultragenyx, Zeto. Read More
